Skip to main content

Table 1. Baselines characteristics of all patients

From: Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

Characteristics

Bedaquiline group (n = 102)

Non-bedaquiline group (n = 100)

p value

Age (years, median/IQR)

37.0 (28.0–52.0)

43.5 (29.0–54.0)

0.08

Gender (n, %), male/female

78 (76.5)/24 (23.5)

71 (71.0)/29 (29.0)

0.77

Cavitary disease at baseline (n, %)

71 (73.2)

73 (73.0)

0.65

Concomitant extra-pulmonary TB (n, %)

20 (19.6)

15 (15.0)

0.39

Concomitant diabetes (n, %)

16 (15.7)

13 (13.0)

0.59

History of TB treatment (n, %)

  

0.85

 New cases

9 (8.8)

8 (8.1)

 

 Previously treated cases

93 (91.2)

91 (91.9)

 

Type of drug resistance (n, %)

  

0.67

 RR

3 (2.9)

5 (5.0)

 

 MDR

74 (72.5)

68 (68.0)

 

 XDR

25 (24.5)

27 (27.0)

 

Drug resistant rate (n, %)/n, % in XDR

   

 Injectable agents

83 (81.4)/25 (100.0)

77 (77.0)/27 (100.0)

0.44/–

 FQs

61 (59.8)/25 (100.0)

55 (55.0)/27 (100.0)

0.49/–

 EMB

57 (55.9)/16 (64.0)

65 (65.0)/24 (88.9)

0.19/0.03*

 INH

97 (95.1)/23 (92.0)

98 (98.0)/26 (96.3)

0.20/0.95

  1. IQR interquartile range, M male, F female, n number, TB tuberculosis, RR rifampicin-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, FQs fluoroquinolones, EMB ethambutol, INH isoniazid. Injectable agents: including Amikacin (Ak), Capremycin (Cm) and Streptomycin (Sm)
  2. * the differences had statistical significance (p < 0.05)